Research indicates that wild-type OPTN can suppress IRF3 activation, whereas ALS-associated mutations (such as Q398X and E478G) lose this inhibitory function, leading to aberrant IRF3 activation [105]. The gene discussed is OPTN; the disease is amyotrophic lateral sclerosis.